# Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

> **NCT05130047** · PHASE2 · COMPLETED · sponsor: **Michael Camilleri, MD** · enrollment: 30 (actual)

## Conditions studied

- Chronic Diarrhea
- Irritable Bowel Syndrome With Diarrhea
- Bile Acid Malabsorption
- Bile Acid Diarrhea
- Bile Acid Malabsorption Syndrome Type II
- Functional Diarrhea

## Interventions

- **DRUG:** Aldafermin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05130047
- **Lead sponsor:** Michael Camilleri, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130047, "Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05130047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*